148 related articles for article (PubMed ID: 34767826)
1. Blockade of Microglial Kv1.3 Potassium Channels by the Peptide HsTX1[R14A] Attenuates Lipopolysaccharide-mediated Neuroinflammation.
Nicolazzo JA; Pan Y; Di Stefano I; Choy KHC; Reddiar SB; Low YL; Wai DCC; Norton RS; Jin L
J Pharm Sci; 2022 Mar; 111(3):638-647. PubMed ID: 34767826
[TBL] [Abstract][Full Text] [Related]
2. A Biodistribution Study of the Radiolabeled Kv1.3-Blocking Peptide DOTA-HsTX1[R14A] Demonstrates Brain Uptake in a Mouse Model of Neuroinflammation.
Reddiar SB; de Veer M; Paterson BM; Sepehrizadeh T; Wai DCC; Csoti A; Panyi G; Nicolazzo JA; Norton RS
Mol Pharm; 2023 Jan; 20(1):255-266. PubMed ID: 36331024
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide influences the plasma and brain pharmacokinetics of subcutaneously-administered HsTX1[R14A], a K
Reddiar SB; Jin L; Wai DCC; Csoti A; Panyi G; Norton RS; Nicolazzo JA
Toxicon; 2021 May; 195():29-36. PubMed ID: 33689790
[TBL] [Abstract][Full Text] [Related]
4. Peripheral Administration of the Kv1.3-Blocking Peptide HsTX1[R14A] Improves Cognitive Performance in Senescence Accelerated SAMP8 Mice.
Pan Y; Kagawa Y; Sun J; Lucas DSD; Takechi R; Mamo JCL; Wai DCC; Norton RS; Jin L; Nicolazzo JA
Neurotherapeutics; 2023 Jul; 20(4):1198-1214. PubMed ID: 37226029
[TBL] [Abstract][Full Text] [Related]
5. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
6. A Fluorescent Peptide Toxin for Selective Visualization of the Voltage-Gated Potassium Channel K
Wai DCC; Naseem MU; Mocsár G; Babu Reddiar S; Pan Y; Csoti A; Hajdu P; Nowell C; Nicolazzo JA; Panyi G; Norton RS
Bioconjug Chem; 2022 Nov; 33(11):2197-2212. PubMed ID: 36330854
[TBL] [Abstract][Full Text] [Related]
7. Enabling Noninvasive Systemic Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] via the Buccal Mucosa.
Jin L; Boyd BJ; Larson IC; Pennington MW; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Jul; 105(7):2173-9. PubMed ID: 27312508
[TBL] [Abstract][Full Text] [Related]
8. Distribution and kinetics of the Kv1.3-blocking peptide HsTX1[R14A] in experimental rats.
Bergmann R; Kubeil M; Zarschler K; Chhabra S; Tajhya RB; Beeton C; Pennington MW; Bachmann M; Norton RS; Stephan H
Sci Rep; 2017 Jun; 7(1):3756. PubMed ID: 28623364
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary Delivery of the Kv1.3-Blocking Peptide HsTX1[R14A] for the Treatment of Autoimmune Diseases.
Jin L; Zhou QT; Chan HK; Larson IC; Pennington MW; Morales RAV; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2016 Feb; 105(2):650-656. PubMed ID: 26869426
[TBL] [Abstract][Full Text] [Related]
10. Prolonged Plasma Exposure of the Kv1.3-Inhibitory Peptide HsTX1[R14A] by Subcutaneous Administration of a Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere Formulation.
Jin L; Pan Y; Pham AC; Boyd BJ; Norton RS; Nicolazzo JA
J Pharm Sci; 2021 Mar; 110(3):1182-1188. PubMed ID: 33065128
[TBL] [Abstract][Full Text] [Related]
11. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo.
Di Lucente J; Nguyen HM; Wulff H; Jin LW; Maezawa I
Glia; 2018 Sep; 66(9):1881-1895. PubMed ID: 30043400
[TBL] [Abstract][Full Text] [Related]
12. A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation.
Rangaraju S; Raza SA; Pennati A; Deng Q; Dammer EB; Duong D; Pennington MW; Tansey MG; Lah JJ; Betarbet R; Seyfried NT; Levey AI
J Neuroinflammation; 2017 Jun; 14(1):128. PubMed ID: 28651603
[TBL] [Abstract][Full Text] [Related]
13. A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
Rashid MH; Huq R; Tanner MR; Chhabra S; Khoo KK; Estrada R; Dhawan V; Chauhan S; Pennington MW; Beeton C; Kuyucak S; Norton RS
Sci Rep; 2014 Mar; 4():4509. PubMed ID: 24676092
[TBL] [Abstract][Full Text] [Related]
14. Expression of Kv1.2 in microglia and its putative roles in modulating production of proinflammatory cytokines and reactive oxygen species.
Li F; Lu J; Wu CY; Kaur C; Sivakumar V; Sun J; Li S; Ling EA
J Neurochem; 2008 Sep; 106(5):2093-105. PubMed ID: 18627436
[TBL] [Abstract][Full Text] [Related]
15. Z-guggulsterone negatively controls microglia-mediated neuroinflammation via blocking IκB-α-NF-κB signals.
Huang C; Wang J; Lu X; Hu W; Wu F; Jiang B; Ling Y; Yang R; Zhang W
Neurosci Lett; 2016 Apr; 619():34-42. PubMed ID: 26879835
[TBL] [Abstract][Full Text] [Related]
16. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins.
Regaya I; Beeton C; Ferrat G; Andreotti N; Darbon H; De Waard M; Sabatier JM
J Biol Chem; 2004 Dec; 279(53):55690-6. PubMed ID: 15498765
[TBL] [Abstract][Full Text] [Related]
17. Microglial Kv1.3 Channels and P2Y12 Receptors Differentially Regulate Cytokine and Chemokine Release from Brain Slices of Young Adult and Aged Mice.
Charolidi N; Schilling T; Eder C
PLoS One; 2015; 10(5):e0128463. PubMed ID: 26011191
[TBL] [Abstract][Full Text] [Related]
18. Kv1.1 expression in microglia regulates production and release of proinflammatory cytokines, endothelins and nitric oxide.
Wu CY; Kaur C; Sivakumar V; Lu J; Ling EA
Neuroscience; 2009 Feb; 158(4):1500-8. PubMed ID: 19118603
[TBL] [Abstract][Full Text] [Related]
19. Malaysian endophytic fungal extracts-induced anti-inflammation in Lipopolysaccharide-activated BV-2 microglia is associated with attenuation of NO production and, IL-6 and TNF-α expression.
Harun A; Vidyadaran S; Lim SM; Cole AL; Ramasamy K
BMC Complement Altern Med; 2015 Jun; 15():166. PubMed ID: 26047814
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity.
Liu J; Xu P; Collins C; Liu H; Zhang J; Keblesh JP; Xiong H
PLoS One; 2013; 8(5):e64904. PubMed ID: 23738010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
